Evidence map›Paper›PMID 37576730›Full record

ArticleJornal vascular brasileiro2023

Successful use of rivaroxaban achieving therapeutic anti-factor xa levels in a morbidly obese patient with acute intermediate-high risk pulmonary embolism.

Kingsley Dah, Mateo Porres-Aguilar, Alan De la Rosa, Swathi Prakash

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Jornal vascular brasileiro, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kingsley DahTexas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, Texas, USA.ORCID 0000-0002-2431-8967
Mateo Porres-AguilarTexas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, Texas, USA.ORCID 0000-0002-2180-3000
Alan De la RosaTexas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, Texas, USA.ORCID 0000-0002-8956-0658
Swathi PrakashTexas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, Texas, USA.ORCID 0000-0001-9503-1237
Texas Tech University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The 2021 International Society on Thrombosis and Haemostasis guidelines recommend using standard DOAC dosages in patients with BMI >40 kg/m

Indexed as

acute pulmonary embolismdirect oral anticoagulantsmorbid obesityrivaroxabanvenous thromboembolism

Identifiers

PMID37576730
PMCPMC10421569
OpenAlexW4382776354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.